Abstract
BackgroundGlatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safety in real life clinical practice.MethodsOne year, prospective, multicentre, observational study performed between 2010 and 2015 in consecutive MS and clinically isolated syndrome patients starting GA as a first (“naïve”) or second (“switcher”) line therapy. Primary endpoint was the annualized relapse rate (ARR) over 1 year of GA treatment (from baseline, V1, to 12 months, V2) in naïve and switchers compared to previous 24 months. Secondary endpoints were: EDSS changes between V1 and V2, frequency of adverse events, and reasons for prescribing and discontinuing GA. Baseline demographics and clinical characteristics were retrieved from medical records, and outcome measures were documented at V1 and V2, and in case of clinical worsening.ResultsOne hundred ninety-four consecutive patients were monitored over 12 months (N = 64 naïve, N = 130 switchers). Side effect profile (naïve = 36%, switchers = 28%) and comorbidities (naïve = 31%, switchers = 15%) were the most frequent reasons to start GA. The ARR was reduced in both naïve and switchers during V1–2 as compared to the 24 months preceding V1 [naïve: 0.0 (0.0–0.0) vs 0.5 (0.5–1.0, p = 2.9e-10); switchers: 0.0 (0.0–0.0) vs 0.5 (0.0–0.5, p = 0.022)]. EDSS at V2 was significantly reduced only in naïve [(1.5 (1.0–2.5) vs 2.0 (1.5–2.5), p = 0.003)]. Naïve status and EDSS at V1 were negatively associated with EDSS change between V1-V2 in multivariable analysis (regression coefficient = − 0.436, p = 0.008, and regression coefficient = − 0.263, p = 6.18e-05, respectively). No new unexpected AE was reported.ConclusionIn our Swiss cohort, GA was prescribed mainly to naïve or switcher MS patients fearing interferon related side effects, with various comorbidities or considering pregnancy, and showed effectiveness and safety comparable with data of previous GA studies.
Highlights
Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS)
We aimed at characterizing Swiss MS patients that started with GA treatment in real life clinical practice, assessing the reasons why GA was currently prescribed, as well as its effectiveness and safety, and if these differ between patients using GA as first or second line MS therapy
Expanded Disability Status Scale (EDSS) at V1 was higher in switchers than in naïve patients (2.5 (2.0–3.8) vs 2.0 (1.5– 2.5)), while the annualized relapse rate (ARR) in the 24 months preceding V1 was higher in naïve than in switchers (0.5 (0.5–1.0) vs 0.5 (0.0–1.5) respectively) (Table 1)
Summary
Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). Despite the lack of head to head trials, their efficacy is often considered superior to GA (especially for monoclonal antibodies), at the expense of a less favourable short and long time safety profile [6,7,8,9,10,11]. Since their introduction, these new compounds have expanded the MS therapeutic landscape and changed treatment algorithms. We aimed at characterizing Swiss MS patients that started with GA treatment in real life clinical practice, assessing the reasons why GA was currently prescribed, as well as its effectiveness and safety, and if these differ between patients using GA as first or second line MS therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have